Appendix Table 3.
Characteristics of Virologic Failure Cases
| Case Number | Group | Psychiatric Diagnosis/HIV | HCVVL, IU/mL | Genotype 1a or 1b | Cirrhosis | Tx Naive | Tx Regimen | Weeks of Treatment Regimen Completed (n/N) | Drug 6 Months Before Tx | Drug During Tx | Daily Adherence, % | Viral and Clinical Outcomes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | DOT | Bipolar disorder | 213 832 | 1a | No | Yes | SOF/RBV | 4/24 | C/O/B | O | 79 | Week 4 VL: 233 110 IU/mL DOT 3×/wk, Tx discontinued at week 4 |
| 2 | SIT | Depression | 1 114 267 | 1b | Yes | Yes | SOF/RBV/IFN | 8/12 | O/B | None | No data | Week 4 VL: 93 692 IU/mL Week 8 VL: 3516IU/mL Tx discontinued because of side effects |
| 3 | SIT | Depression | 188 936 | 1a | No | Yes | SOF/LDV | 8/8 | No | B | 43 | ETR, no SVR4 or SVR12 |
| 4 | SIT | Depression | 2 471 964 | 1a | No | Yes | SOF/LDV | 8/8 | C/O | C/O | 31 | ETR, no SVR4 or SVR12 |
| 5 | GT | Depression | 7 300 001 | 1a | No | Yes | SOF/LDV | 12/12 | C/O | C/O | 38 | No ETR UD at weeks 4 and 8 |
| 6 | GT | None | 12 143 424 | 1a | No | Yes | SOF/RBV | 12/24 | C/O | O | 45 | Week 4 VL: 43 IU/mL Week 8 VL: 585 602 IU/mL Incarcerated |
| 7 | SIT | None | 15 961 170 | 1a | Yes | Yes | SOF/LDV | 12/12 | C/O | O | 82 | ETR, no SVR |
| 8 | GT | Depression HIV | 19 508 733 | 1a | No | Yes | SOF/LDV | 7/12 | C/B | C/O | 91 | UD at week 4 Deceased: cardiac |
| 9 | SIT | Depression | 621 760 | 1a | No | Yes | SOF/LDV | 8/12 | O/B | None | 86 | UD at week 8 Deceased: MVA |
B = benzodiazepines; C = cocaine; DOT = directly observed therapy; ETR = end-of-treatment response; GT = group treatment; HCV = hepatitis C virus; IFN = pegylated interferon; LDV = ledipasvir; MVA = motor vehicle accident; O = opioids; RBV = ribavirin; SIT = self-administered individual treatment; SOF = sofosbuvir; SVR = sustained virologic response; SVR4 = SVR at week 4; SVR12 = SVR at week 12; Tx = treatment; UD = undetectable; VL = viral load.